<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647945</url>
  </required_header>
  <id_info>
    <org_study_id>PAH-70522</org_study_id>
    <nct_id>NCT01647945</nct_id>
  </id_info>
  <brief_title>FK506 (Tacrolimus) in Pulmonary Arterial Hypertension</brief_title>
  <acronym>TransformPAH</acronym>
  <official_title>Single-Center Randomized Controlled Phase II Study of Safety and Efficacy of FK-506 (Tacrolimus) in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edda Spiekerkoetter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mutations in bone morphogenetic protein receptor 2 (BMPR2) are present in &gt;80% of familial
      and ~20% of sporadic pulmonary arterial hypertension (PAH) patients. Furthermore
      dysfunctional BMP signaling is a general feature of pulmonary hypertension even in
      non-familial PAH.

      We therefore hypothesized that increasing BMP signaling might prevent and reverse the
      disease. We screened &gt; 3500 FDA approved drugs for their propensity to increase BMP signaling
      and found FK506 (Tacrolimus) to be a strong activator of BMP signaling. Tacrolimus restored
      normal function of pulmonary artery endothelial cells, prevented and reversed experimental
      PAH in mice and rats.

      Given that Tacrolimus is already FDA approved with a known side-effect profile, it is an
      ideal candidate drug to use in patients with pulmonary arterial hypertension.

      The aims of our trial are:

        1. Establish the Safety of FK506 in patients with PAH.

        2. Evaluate the Efficacy of FK506 in PAH

        3. Identify ideal candidates for future FK506 phase III clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      Randomized, placebo-controlled, four arm clinical trial.

      Sample Size: 10 subjects in each arm, Total enrollment = 40 patients.

        1. 10 patients: FK-506 blood level: 3 - 5 ng/ml

        2. 10 patients: FK-506 blood level: 2 - 3 ng/ml

        3. 10 patients: FK-506 level: &lt; 2.0 ng/ml

        4. 10 patients: Placebo

      Study Duration:

      16 weeks

      Primary Endpoints:

      1) Safety of low-dose FK506 in PAH

      Secondary Objectives/Endpoints:

        1. Combined Clinical Events/Time to Clinical Worsening @ 16 weeks:

             -  All cause mortality

             -  Transplantation

             -  Atrial septostomy

             -  Need for escalation of therapies as deemed by site investigator

             -  Worsening of NYHA/WHO classification by at least 1 point.

             -  Hospitalization for right heart failure.

        2. Change in 6MWD at 16 weeks

        3. Change in NT-Pro-BNP at 16 weeks

        4. Change in Uric Acid at 16 weeks

        5. Change in DLCO at 16 weeks

        6. Change in novel RV parameters by transthoracic echocardiography: Change in RV size, RA
           size, RV function, TAPSE, RVSP
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Low-dose FK-506 in PAH</measure>
    <time_frame>18 weeks</time_frame>
    <description>Total number of adverse events measured between baseline and end of study at 18 weeks as reported by study subjects such as nausea/diarrhea, URI, sinus congestion, infection, fluid retention/edema, cough, headache, bronchitis, fatigue, drug reaction/hives, flushing, anxiety, tremor, fever, shingles, SOB, insomnia, pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Combined Clinical Events</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
    <description>Combined Clinical Events @ 16 weeks:
Number of patients who died Number of patients who got transplanted Number of patients who needed escalation of therapies Number of patients who had worsening of NYHA/WHO classification by at least 1 point Number of patients who require hospitalization for right heart failure
Low numbers would suggest either efficacy of the study drug or slowly progression of disease that is studied during the 16 week study period or short observation period or small study population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Low-dose FK-506 in Pulmonary Arterial Hypertension (PAH) Measured by Change in 6-min Walk Distance (6MWD)</measure>
    <time_frame>baseline to 16 weeks</time_frame>
    <description>Change in 6MWD in meter between baseline and 16 weeks
A large number would indicate an increase in exercise capacity</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FK506 level &lt; 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FK506 level 2-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FK506 level 3-5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK506 level &lt; 2 ng/ml</intervention_name>
    <description>FK506 goal trough blood level &lt; 2 ng/ml</description>
    <arm_group_label>FK506 level &lt; 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK506 level 2-3 ng/ml</intervention_name>
    <description>FK506 goal trough blood level 2-3 ng/ml</description>
    <arm_group_label>FK506 level 2-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK506 level 3-5 ng/ml</intervention_name>
    <description>FK506 goal trough blood level 3-5 ng/ml</description>
    <arm_group_label>FK506 level 3-5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 and &lt; 70 years

          2. Diagnosis of WHO Group I Pulmonary Arterial Hypertension (PAH) (Idiopathic (I)PAH,
             Heritable PAH (including Hereditary Hemorrhagic Telangiectasia), Associated (A)PAH
             (including collagen vascular disorders, drugs+toxins exposure, congenital heart
             disease, and portopulmonary disease).

          3. Stable on active PAH treatment including any prostacycline or phosphodiesterase
             inhibitors and the endothelin antagonist Ambrisentan alone or in combination
             (stability defined as: &lt;10% change in 6MWD, no change in NYHA class, no
             hospitalization or addition of PAH therapy for at least 3 months).

          4. Previous Right Heart Catheterization that documented:

               1. Mean PAP ≥ 25 mmHg.

               2. Pulmonary capillary wedge pressure &lt; 15 mmHg.

               3. Pulmonary Vascular Resistance ≥ 3.0 Wood units or 240 dynes/sec/cm5

          5. WHO functional class I to IV as judged by the investigator.

        Exclusion Criteria:

          1. WHO Group II - V Pulmonary Hypertension.

          2. Current or prior experimental PAH treatments within the last 6 months (including but
             not limited to tyrosine kinase inhibitors, rho-kinase inhibitors, or cGMP modulators).

          3. Current active treatment with the dual endothelin receptor antagonist bosentan.

          4. TLC &lt; 60% predicted; if TLC b/w 60 and 70% predicted, high resolution computed
             tomography must be available to exclude significant interstitial lung disease.

          5. FEV1 / FVC &lt; 70% predicted and FEV1 &lt; 60% predicted

          6. Significant left-sided heart disease (based on screening Echocardiogram):

               1. Significant aortic or mitral valve disease

               2. Diastolic dysfunction ≥ Grade II

               3. LV systolic function &lt; 45%

               4. Pericardial constriction

               5. Restrictive cardiomyopathy

               6. Significant coronary disease with demonstrable ischemia.

          7. Chronic renal insufficiency defined as an estimated creatinine clearance &lt; 30 ml/min
             (by MDRD equation).

          8. Current atrial arrhythmias not under optimal control.

          9. Uncontrolled systemic hypertension: SBP &gt; 160 mm or DBP &gt; 100mm

         10. Severe hypotension: SBP &lt; 80 mmHg.

         11. Pregnant or breast-feeding.

         12. Psychiatric, addictive, or other disorder that compromises patient's ability to
             provide informed consent, follow study protocol, and adhere to treatment instructions.

         13. Active cyclosporine use.

         14. Known allergy or hypersensitivity to FK-506.

         15. Planned initiation of cardiac or pulmonary rehabilitation during period of study.

         16. Human Immunodeficiency Virus infection.

         17. Moderate to severe hepatic dysfunction with a Pugh score &gt;10.

         18. Hyperkalemia defined as Potassium &gt; 5.1 mEq/L at screening .

         19. Known active infection requiring antibiotic, antifungal, or antiviral therapies.

         20. Co-morbid conditions that would impair a patient's exercise performance and ability to
             assess WHO functional class, including but not limited to chronic low-back pain or
             peripheral musculoskeletal problems.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edda Spiekerkoetter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roham Zamanian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://wallcenter.stanford.edu</url>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <results_first_submitted>June 24, 2016</results_first_submitted>
  <results_first_submitted_qc>August 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2016</results_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Edda Spiekerkoetter</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>PAH WHO group 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: placebo pill</description>
        </group>
        <group group_id="P2">
          <title>FK506 Level &lt; 2</title>
          <description>FK506 level &lt; 2 ng/ml: FK506 goal trough blood level &lt; 2 ng/ml</description>
        </group>
        <group group_id="P3">
          <title>FK506 Level 2-3</title>
          <description>FK506 level 2-3 ng/ml: FK506 goal trough blood level 2-3 ng/ml</description>
        </group>
        <group group_id="P4">
          <title>FK506 Level 3-5</title>
          <description>FK506 level 3-5 ng/ml: FK506 goal trough blood level 3-5 ng/ml</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: placebo pill</description>
        </group>
        <group group_id="B2">
          <title>FK506 Level &lt; 2</title>
          <description>FK506 level &lt; 2 ng/ml: FK506 goal trough blood level &lt; 2 ng/ml</description>
        </group>
        <group group_id="B3">
          <title>FK506 Level 2-3</title>
          <description>FK506 level 2-3 ng/ml: FK506 goal trough blood level 2-3 ng/ml</description>
        </group>
        <group group_id="B4">
          <title>FK506 Level 3-5</title>
          <description>FK506 level 3-5 ng/ml: FK506 goal trough blood level 3-5 ng/ml</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="38" upper_limit="53"/>
                    <measurement group_id="B2" value="35" lower_limit="24" upper_limit="45"/>
                    <measurement group_id="B3" value="39" lower_limit="25" upper_limit="51"/>
                    <measurement group_id="B4" value="45" lower_limit="42" upper_limit="48"/>
                    <measurement group_id="B5" value="41" lower_limit="34" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of Low-dose FK-506 in PAH</title>
        <description>Total number of adverse events measured between baseline and end of study at 18 weeks as reported by study subjects such as nausea/diarrhea, URI, sinus congestion, infection, fluid retention/edema, cough, headache, bronchitis, fatigue, drug reaction/hives, flushing, anxiety, tremor, fever, shingles, SOB, insomnia, pain</description>
        <time_frame>18 weeks</time_frame>
        <population>all study subjects who started the study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: placebo pill</description>
          </group>
          <group group_id="O2">
            <title>FK506 Level &lt; 2</title>
            <description>FK506 level &lt; 2 ng/ml: FK506 goal trough blood level &lt; 2 ng/ml</description>
          </group>
          <group group_id="O3">
            <title>FK506 Level 2-3</title>
            <description>FK506 level 2-3 ng/ml: FK506 goal trough blood level 2-3 ng/ml</description>
          </group>
          <group group_id="O4">
            <title>FK506 Level 3-5</title>
            <description>FK506 level 3-5 ng/ml: FK506 goal trough blood level 3-5 ng/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Low-dose FK-506 in PAH</title>
          <description>Total number of adverse events measured between baseline and end of study at 18 weeks as reported by study subjects such as nausea/diarrhea, URI, sinus congestion, infection, fluid retention/edema, cough, headache, bronchitis, fatigue, drug reaction/hives, flushing, anxiety, tremor, fever, shingles, SOB, insomnia, pain</description>
          <population>all study subjects who started the study</population>
          <units>number of AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Combined Clinical Events</title>
        <description>Combined Clinical Events @ 16 weeks:
Number of patients who died Number of patients who got transplanted Number of patients who needed escalation of therapies Number of patients who had worsening of NYHA/WHO classification by at least 1 point Number of patients who require hospitalization for right heart failure
Low numbers would suggest either efficacy of the study drug or slowly progression of disease that is studied during the 16 week study period or short observation period or small study population</description>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>Subjects were included who finished the 16 week study period. A total of 3 participants did not complete the study</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: placebo pill</description>
          </group>
          <group group_id="O2">
            <title>FK506 Level &lt; 2</title>
            <description>FK506 level &lt; 2 ng/ml: FK506 goal trough blood level &lt; 2 ng/ml</description>
          </group>
          <group group_id="O3">
            <title>FK506 Level 2-3</title>
            <description>FK506 level 2-3 ng/ml: FK506 goal trough blood level 2-3 ng/ml</description>
          </group>
          <group group_id="O4">
            <title>FK506 Level 3-5</title>
            <description>FK506 level 3-5 ng/ml: FK506 goal trough blood level 3-5 ng/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Combined Clinical Events</title>
          <description>Combined Clinical Events @ 16 weeks:
Number of patients who died Number of patients who got transplanted Number of patients who needed escalation of therapies Number of patients who had worsening of NYHA/WHO classification by at least 1 point Number of patients who require hospitalization for right heart failure
Low numbers would suggest either efficacy of the study drug or slowly progression of disease that is studied during the 16 week study period or short observation period or small study population</description>
          <population>Subjects were included who finished the 16 week study period. A total of 3 participants did not complete the study</population>
          <units>Combined Number of Clinical Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Low-dose FK-506 in Pulmonary Arterial Hypertension (PAH) Measured by Change in 6-min Walk Distance (6MWD)</title>
        <description>Change in 6MWD in meter between baseline and 16 weeks
A large number would indicate an increase in exercise capacity</description>
        <time_frame>baseline to 16 weeks</time_frame>
        <population>Only subjects were included who finished the 16-week study 3 patients did not finish</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: placebo pill</description>
          </group>
          <group group_id="O2">
            <title>FK506 Level &lt; 2</title>
            <description>FK506 level &lt; 2 ng/ml: FK506 goal trough blood level &lt; 2 ng/ml</description>
          </group>
          <group group_id="O3">
            <title>FK506 Level 2-3</title>
            <description>FK506 level 2-3 ng/ml: FK506 goal trough blood level 2-3 ng/ml</description>
          </group>
          <group group_id="O4">
            <title>FK506 Level 3-5</title>
            <description>FK506 level 3-5 ng/ml: FK506 goal trough blood level 3-5 ng/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Low-dose FK-506 in Pulmonary Arterial Hypertension (PAH) Measured by Change in 6-min Walk Distance (6MWD)</title>
          <description>Change in 6MWD in meter between baseline and 16 weeks
A large number would indicate an increase in exercise capacity</description>
          <population>Only subjects were included who finished the 16-week study 3 patients did not finish</population>
          <units>meter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="3.5" upper_limit="38.25"/>
                    <measurement group_id="O2" value="0" lower_limit="-20.25" upper_limit="3"/>
                    <measurement group_id="O3" value="41" lower_limit="-9.5" upper_limit="59"/>
                    <measurement group_id="O4" value="0" lower_limit="-20" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from every study subject who started the study regardless whether the subject finished the study. Events were collected during the time frame between baseline and 18 weeks.</time_frame>
      <desc>Of note the study drug was stopped at 16 weeks, an additional observation period of 2 weeks was used to capture possible adverse events of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: placebo pill</description>
        </group>
        <group group_id="E2">
          <title>FK506 Level &lt; 2</title>
          <description>FK506 level &lt; 2 ng/ml: FK506 goal trough blood level &lt; 2 ng/ml</description>
        </group>
        <group group_id="E3">
          <title>FK506 Level 2-3</title>
          <description>FK506 level 2-3 ng/ml: FK506 goal trough blood level 2-3 ng/ml</description>
        </group>
        <group group_id="E4">
          <title>FK506 Level 3-5</title>
          <description>FK506 level 3-5 ng/ml: FK506 goal trough blood level 3-5 ng/ml</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <description>One patient developed hemoptysis during the observation weeks 16 -18, after the study drug had already been stopped (at week 16).
The hemoptysis occured in the setting of a strep throat infection that was treated with antibiotics.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid retention</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>not requiring increase in diuretics</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/ Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to slow patient recruitment in single academic center we recruited fewer patients than originally expected.
Follow-up multicenter phase IIb efficacy trial is planned</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Edda Spiekerkoetter</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-724-1493</phone>
      <email>eddas@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

